- Home
- GOSS vs CLNN Comparison
GOSS vs CLNN Comparison
Compare GOSS & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | CLNN |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | 79 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 85.7M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GOSS | CLNN |
|---|---|---|
| Price | $0.17 | $5.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $4.19 | ★ $33.75 |
| AVG Volume (30 Days) | ★ 15.1M | 96.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | $17.64 |
| Revenue Next Year | $201.64 | $19,516.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $3.25 |
| 52 Week High | $3.87 | $13.50 |
Technical Indicators
Market Signals| Indicator | GOSS | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 34.86 | 43.94 |
| Support Level | $0.16 | $5.40 |
| Resistance Level | $0.36 | $6.71 |
| Average True Range (ATR) | 0.02 | 0.39 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 47.73 | 38.84 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.